ARG1 and cancer: Based on the previous pre-clinical and clinical vaccination trials targeting proteins involved in immune regulation from CCIT-DK (13, 14, 16–19), we planned a trial with a therapeutic ARG1 peptide vaccine for patients with high MDSC-expressing cancers treated at the Oncology Department at Herlev Hospital.